LMY-920
LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)
What will happen during the trial?
In this open label, dose escalation study, up to four dose levels of autologous BAFF ligand CAR-T cells (LMY-920) will be evaluated for treatment relapsed and refractory myeloma. BAFF receptor family includes B-cell activating factor receptor (BR3), B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). The maximum tolerated dose (MTD) of LMY-920 will be determined using dose-escalation 3+3 design. The primary goal of this study is to determine recommended phase II dose of human LMY-920 in patients with relapsed or refractory myeloma.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 30 patients (estimated)
- Sponsors
- Luminary Therapeutics
- Collaborators
- Cleveland Clinic - Taussig Cancer Center, Case Western Reserve University
- Tags
- CAR T Cell, B-Cell Activating Factor (BAFF)
- Trial Type
- Treatment
- Last Update
- 11 months ago
- SparkCures ID
- 1313
- NCT Identifier
- NCT05546723
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.